Generation of a novel long-acting thymosin alpha1-Fc fusion protein and its efficacy for the inhibition of breast cancer in vivo
Open Access
- 1 December 2018
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 108, 610-617
Abstract
No abstract availableKeywords
Funding Information
- Fundamental Research Funds for the Central Universities (2632018ZD04)
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- National Natural Science Foundation of China (31300643)
- National Natural Science Foundation of China (31370505)
This publication has 55 references indexed in Scilit:
- Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyondAnnals of the New York Academy of Sciences, 2012
- Autocrine IL-2 is required for secondary population expansion of CD8+ memory T cellsNature Immunology, 2011
- The effects of LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, in a randomized, placebo‐controlled, double‐blind study of overweight/obese patients with type 2 diabetes: the EGO studyDiabetes, Obesity and Metabolism, 2011
- Influence of carbohydrates on the stability and structure of a hyperglycosylated human interferon alpha muteinBiochimie, 2010
- Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedsideBritish Journal of Haematology, 2010
- Large Randomized Study of Thymosin α 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2010
- A novel human CD4+ T‐cell inducer subset with potent immunostimulatory propertiesEuropean Journal of Immunology, 2009
- Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technologyCurrent Opinion in Biotechnology, 2009
- Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cellsNature, 2006
- Thymosin α1 inhibits mammary carcinogenesis in Fisher ratsPeptides, 2002